Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Applied Biochemistry and Biotechnology|January 1, 1991
Bioconversion of a L-carnitin precursor in a one- or two-phase systemG Bare, P Jacques, J B Hubert, et al.Epidemiology and Infection|December 16, 2000
Is cytomegalovirus infection a co-factor in HIV-1 disease progression?M Robain, F Boufassa, J B Hubert, et al.AIDS (London, England)|February 24, 2001
Cytomegalovirus seroconversion as a cofactor for progression to AIDSM Robain, F Boufassa, J B Hubert, et al.International Journal of Epidemiology|December 5, 1998
Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/microL. SEROCO & HEMOCO Study GroupN Carré, F Boufassa, J B Hubert, et al.AIDS (London, England)|September 26, 1997
Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study GroupL Meyer, M Magierowska, J B Hubert, et al.La Revue De Medecine Interne|January 1, 1995
[Effect of primary prevention of Pneumocystis carinii pneumonia on the inaugural clinical and biological presentation of AIDS: 624 cases (Aquitaine Cohort, 1985-1994)]P Morlat, J B Hubert, G Chêne, et al.BMJ (Clinical Research Ed.)|July 31, 1993
Migraine and risk of ischaemic stroke: a case-control studyC Tzourio, S Iglesias, J B Hubert, et al.The Journal of Infectious Diseases|August 7, 1999
CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study GroupsL Meyer, M Magierowska, J B Hubert, et al.AIDS (London, England)|June 10, 1998
Determinants of delayed diagnosis of HIV infection in France, 1993-1995E Couturier, V Schwoebel, C Michon, et al.Revue D'Epidemiologie Et De Sante Publique|April 10, 2003
[Management of the bank of biological material in the hospital-based SEROCO and HEMOCO cohorts of HIV-infected patients]L Meyer, M Gharib, J Lerable, et al.Pageof 2